Company intelligence / Profile preview

Firebrick Pharma

Melbourne, Victoria, Australiafirebrickpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Nasodine Nasal Spray has been launched in the USA and Singapore in 2024. A Phase 2 randomized controlled multi-dose trial in COVID-19 patients achieved its primary endpoint in 2023, showing that Nasodine dosing 8 times daily over 3 days leads to 100% clearance of SARS-CoV-2 from the nasal passages. The company also successfully defended its patent against a competitor nasal spray in Singapore in 2025.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (povidone-iodine/PVP-I formulations)
Industry: Biotech

Drug pipeline

1 asset

Nasodine

Unknown

Partnerships

SV More Pharma (Philippines)Pharma Nutria (Philippines)

Beyond the preview

Go deeper on Firebrick Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Firebrick Pharma.

Explore the full profile